IE
HEPA

Israel Englander’s Hepion Pharmaceuticals HEPA Stock Holding History

Israel Englander’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-29
Closed -$91 – 5356
2020
Q3 		$91 Buy
+29
New +$104K ﹤0.01% 4239

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Israel Englander's HEPA Position: Q4 2020 in Review

Israel Englander sold out of Hepion Pharmaceuticals (HEPA) in Q4 2020, closing a stake of 29 shares — an estimated $91 sold.

Israel Englander first reported a position in HEPA in Q3 2020 and held it in 1 quarter. The position peaked at $91 in Q3 2020. 29 funds tracked by Wall St. Rank hold HEPA as of Q4 2020.

  • Israel Englander reported no remaining Hepion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Israel Englander sold 29 Hepion Pharmaceuticals shares in Q4 2020, an estimated $91.
  • Israel Englander first reported a position in Hepion Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Israel Englander's Hepion Pharmaceuticals position peaked at $91 in Q3 2020.
  • 29 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q4 2020.

Based on Millennium Management's 13F filing for Q4 2020, filed 16 Feb 2021.